Syndax Pharmaceuticals (SNDX) Long-Term Investments (2017 - 2025)

Syndax Pharmaceuticals' Long-Term Investments history runs 5 years deep, the most recent figure standing at $20.1 million for Q3 2025.

• In Q3 2025, Long-Term Investments rose 100.88% year-over-year to $20.1 million; the TTM figure through Sep 2025 stood at $20.1 million (up 100.88% YoY), while the FY2024 annual figure was $119.5 million, up 300.68% from the prior year.
• Long-Term Investments was $20.1 million for Q3 2025 at Syndax Pharmaceuticals, down from $62.6 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $119.5 million in Q4 2024 to a low of $5.5 million in Q4 2022.
• Historically, Long-Term Investments has averaged $39.9 million across 4 years, with a median of $20.1 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Long-Term Investments jumped 445.42% in 2023, then plunged 36.14% in 2024.
• A 4-year view of Long-Term Investments shows it stood at $5.5 million in 2022, then surged by 445.42% to $29.8 million in 2023, then jumped by 300.68% to $119.5 million in 2024, then plunged by 83.14% to $20.1 million in 2025.
• The last three Long-Term Investments figures came in at $20.1 million (Q3 2025), $62.6 million (Q2 2025), and $89.9 million (Q1 2025), per Business Quant data.